Form 4: IGM Biosciences Director Michael Lee Granted Stock Options

Michael Lee, a director of IGM Biosciences, was granted stock options for 29,400 shares of common stock at an exercise price of $9.95 on March 12, 2024.

Summary

• Michael Lee, a director of IGM Biosciences, filed a Form 4 on March 14, 2024, reporting a transaction that occurred on March 12, 2024.
• He was granted stock options for 29,400 shares of IGM Biosciences common stock with an exercise price of $9.95.
• The options vest in monthly installments after the Issuer's first annual stockholder meeting following the grant date, with full vesting occurring on the earlier of the 12-month anniversary of the Annual Meeting or the date of the Issuer's next annual stockholder meeting, subject to continued service.
• Lee is a managing director of Redmile Group, LLC and holds the stock option as a nominee on behalf of Redmile, assigning all economic, pecuniary, and voting rights to Redmile.
• Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities.
• Jeremy Green, as the principal of Redmile, may also be deemed to beneficially own the stock option, but disclaims beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral. The fact that a director is receiving options is mildly positive as it aligns interests.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Management Comments

• Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates.
• Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotechnology industry for compensating board members.
• The vesting schedule described is typical, designed to retain board members and align their interests with long-term shareholder value.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates